Results 41 to 50 of about 1,538,497 (307)

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst, Mario Abruscato, Susanne Hövelmann, Pfeilschifter, Waltraud, Abruscato, Mario Giovanni Rosario, Hövelmann, Susanne, Horst Baas, Waltraud Pfeilschifter   +7 more
core   +1 more source

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation

Clinical Case Reports, 2022
Venous thromboembolism is often treated with direct oral anticoagulants. In order for direct oral anticoagulants to be effective, patients must adhere to a specific dosing strategy.
Trisha E Jethwa, Kaitlin M Moran, Michael J Maniaci   +2 more
doaj   +1 more source

Oral anticoagulants for stroke prevention in nonvalvular AF [PDF]

, 2017
YesWarfarin and direct oral anticoagulants (DOACs) have been shown to reduce the risk of stroke in patients with atrial fibrillation, yet many patients are still not being anticoagulated.
Petty, Duncan R., Kristina Medlinskiene, Medlinskiene, Kristina, Duncan Petty   +3 more
core   +1 more source

Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration

Ophthalmology Science
Purpose: To determine differences in visual acuity (VA) outcomes in eyes of patients on antithrombotics (antiplatelet agents and anticoagulants) that develop submacular hemorrhage (SMH) compared with eyes of patients who are not on antithrombotics and ...
Hemal P. Patel, MD, Cason B. Robbins, MD, Jamie J. Karl, MD, Peter Weng, MD, PhD, Lejla Vajzovic, MD, FASRS, Sharon Fekrat, MD, FASRS   +5 more
doaj   +1 more source

Management of Patients Using Oral Anticoagulant Agent in Dental Practice

Bezmiâlem Science, 2019
An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used ...
Özge DOĞANAY, Türker YÜCESOY, Alper ALKAN   +2 more
doaj   +1 more source

A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)

Haematologica, 2018
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Laura Green, Joachim Tan, Joan K Morris, Raza Alikhan, Nicola Curry, Tamara Everington, Rhona Maclean, Khalid Saja, Simon Stanworth, Campbell Tait, Peter MacCallum   +10 more
doaj   +1 more source

Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation

Monaldi Archives for Chest Disease, 2020
The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano, Matteo Parollo, Ester Taurino, Elena Venturi, Massimo Santini   +4 more
doaj   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Reversal of Oral Anticoagulation [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
Although the use of dabigatran and rivaroxaban are increasing, data on the reversal of their effects are limited. The lack of reliable monitoring methods and specific reversal agents renders treatment strategies empirical, and as a result, treatment consists mainly of supportive measures.
Jonathan L, Thigpen, Nita A, Limdi
openaire   +2 more sources

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal, Gowtham Yerneni, Kim J. Griffin, Nicolas Thompson, Ken Uchino, Irene Katzan, Dolora Wisco, Abeer Farrag, Jayashree Sundarajan, Andrew Russman, M. Shazam Hussain   +10 more
wiley   +1 more source